Literature DB >> 22075853

Jaundice due to suspected statin hepatotoxicity: a case series.

Ottar M Bergmann1, Gudjon Kristjansson, Jon G Jonasson, Einar S Björnsson.   

Abstract

Statin drugs are widely used worldwide and are generally considered safe and well tolerated. Only small proportion of patients receiving statins develop elevations of liver enzymes and an even smaller proportion will have clinically significant hepatitis induced by statins. We describe four patients with jaundice caused by drug-induced liver injury, where the most likely agent was a statin drug, over a period of approximately three year in Iceland. We calculate the risk of jaundice caused by statin drugs, from sale in the whole country of Iceland, to be one in 17,434 users a year. This is a higher risk than has previously been estimated and we challenge the current opinion that statins rarely cause clinically significant drug-induced liver injury and encourage alertness when managing patients with statins with regard to clinical signs of hepatitis before jaundice occurs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075853     DOI: 10.1007/s10620-011-1950-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Fatal liver failure with atorvastatin.

Authors:  Ludwig Perger; Malcolm Kohler; Karin Fattinger; Renata Flury; Peter J Meier; Christiane Pauli-Magnus
Journal:  J Hepatol       Date:  2003-12       Impact factor: 25.083

2.  Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden.

Authors:  Einar Björnsson; Pernilla Jerlstad; Annika Bergqvist; Rolf Olsson
Journal:  Scand J Gastroenterol       Date:  2005-09       Impact factor: 2.423

Review 3.  Atorvastatin associated liver disease.

Authors:  A T Clarke; P R Mills
Journal:  Dig Liver Dis       Date:  2006-06-13       Impact factor: 4.088

4.  Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge.

Authors:  C Benichou; G Danan; A Flahault
Journal:  J Clin Epidemiol       Date:  1993-11       Impact factor: 6.437

Review 5.  Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature.

Authors:  A Schattner; N Kozak; J Friedman
Journal:  Am J Med Sci       Date:  2001-10       Impact factor: 2.378

Review 6.  Drug-induced liver injury in clinical trials: as rare as hens' teeth.

Authors:  Timothy J Davern; Naga Chalasani
Journal:  Am J Gastroenterol       Date:  2009-04-07       Impact factor: 10.864

7.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Authors:  Naga Chalasani; Hisham Aljadhey; Joe Kesterson; Michael D Murray; Stephen D Hall
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

8.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.

Authors:  R H Bradford; C L Shear; A N Chremos; C Dujovne; M Downton; F A Franklin; A L Gould; M Hesney; J Higgins; D P Hurley
Journal:  Arch Intern Med       Date:  1991-01

Review 9.  The pathology of drug-induced liver injury.

Authors:  David E Kleiner
Journal:  Semin Liver Dis       Date:  2009-10-13       Impact factor: 6.115

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  4 in total

1.  Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.

Authors:  Maciej Banach; Manfredi Rizzo; Peter P Toth; Michel Farnier; Michael H Davidson; Khalid Al-Rasadi; Wilbert S Aronow; Vasilis Athyros; Dragan M Djuric; Marat V Ezhov; Robert S Greenfield; G Kees Hovingh; Karam Kostner; Corina Serban; Daniel Lighezan; Zlatko Fras; Patrick M Moriarty; Paul Muntner; Assen Goudev; Richard Ceska; Stephen J Nicholls; Marlena Broncel; Dragana Nikolic; Daniel Pella; Raman Puri; Jacek Rysz; Nathan D Wong; Laszlo Bajnok; Steven R Jones; Kausik K Ray; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2015-03-14       Impact factor: 3.318

Review 2.  Statins and its hepatic effects: Newer data, implications, and changing recommendations.

Authors:  Jimmy Jose
Journal:  J Pharm Bioallied Sci       Date:  2016 Jan-Mar

3.  Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe.

Authors:  Silje Bergland Ellingsen; Elisabet Nordmo; Knut Tore Lappegård
Journal:  Clin Med Insights Case Rep       Date:  2017-09-25

4.  Dyslipidemia is a Risk Factor for the Incidence and Severity of Drug-Induced Liver Injury (DILI): A Retrospective Population-Based Study in China.

Authors:  Xu Li; Le Wang; Dezhao Li; Junqi Niu; Pujun Gao
Journal:  Med Sci Monit       Date:  2019-05-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.